Case Study

Case study discussion – Therapies for symptomatic hypertrophic cardiomyopathy patients

Course Overview

Accreditation for this course expired on December 27th, 2022. If you would still like an activity completion certificate, send your request to contact@thehcmacademy.com.

This case study features expert discussion surrounding a real HCM patient and is designed to raise awareness for best practice treatment of symptomatic patients with obstructive HCM and provide you with an understanding of how heart failure symptoms should be managed. It assists clinicians in community practice or those with an interest in HCM management to:  

  • understand the underlying etiology of heart failure symptoms in obstructive HCM  
  • correctly manage heart failure symptoms of obstructive HCM 
  • understand the advanced treatment options available for management of heart failure symptoms that are refractory to maximum medical management 
  • know when referral to an HCM expert center is appropriate 

This case study discussion is designed to be completed in 45 minutes.  

Target audience: Family/general physicians, general/community cardiologists, cardiac nurses, paediatricians, paediatric nurses, genetic counselors 

Funding disclosure: This activity is supported by educational grant funding from BMS, Cytokinetics and Sanofi.  

Learners may participate in this educational activity free of charge. 

  • Heart failure symptoms in HCM 
  • Pharmacological treatment of heart failure symptoms in obstructive HCM 
  • Invasive therapies for heart failure symptoms refractory to pharmacotherapy 
  • Future therapies 

At the end of this case study, delegates should be able to: 

  • Outline steps to mitigate heart failure symptoms in patients with obstructive HCM and apply these to a sample patient 
  • Explain advanced therapy options for patients with obstructive HCM that is refractory to pharmacotherapy and apply this knowledge to an example patient 
  • Compare the risks and benefits of alcohol septal ablation and surgical myectomy, and apply to treatment decision-making for a sample patient 

Accreditation for this course has expired. You may view the program, but CME / CE is no longer available and no certificate will be issued.

Faculty disclosure: 

Dr Martin Maron, MD, Director of the Hypertrophic Cardiomyopathy Center and Research Institute at Tufts Medical Center and the Chanin T. Mast Hypertrophic Cardiomyopathy Center in Morristown Medical Center, has received financial compensation for consulting for Cytokinetics and Imbria, and received research grants from Takeda and iRhythm. 

Dr Anjali Tiku Owens, MD, Medical Director of the Advanced Heart Failure and Transplant Cardiology, Penn Center for Inherited Cardiovascular Disease/ University of Pennsylvania, received financial compensation for consulting for MyoKardia/BMS and Cytokinetics. 

Disclosure of educational planners: 

Lauren Tebay, BA (mod), PhD, Senior Medical Writer, PCM Scientific, has no relevant conflicts of interest to disclose.  

Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose. 

All relevant financial relationships have been mitigated.